Patents Assigned to TLL Pharmaceutical, LLC
  • JAK1 selective inhibitors and uses thereof
    Patent number: 10738060
    Abstract: The new 1H-furo[3,2-b]imidazo[4,5-d]pyridine derivatives are selective Jak1 kinase inhibitors useful in treating disorders related to Jak1 activities such as autoimmune diseases or disorders, inflammatory diseases or disorders, and cancer or neoplastic diseases or disorders.
    Type: Grant
    Filed: September 30, 2017
    Date of Patent: August 11, 2020
    Assignee: TLL Pharmaceutical, LLC
    Inventor: Congxin Liang